KHKatsuyoshi Hashine

Katsuyoshi Hashine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katsuyoshi Hashine has a total of 300 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association between nerve-sparing techniques and oncologic outcomes following radical prostatectomy: A multi-institutional analysis from the Medical Investigation Cancer Network (MICAN) study

    by Katsuyoshi Hashine, Noriyoshi Miura, Hirofumi Sogabe, Yusuke Fukatani, Takuya Tsujioka, Kosuke Seto, Natsumi Yamashita, Akira Yano, Iku Ninomiya, Masafumi Matsumura, et al.

  • Validation of the NCCN Subclassification for Intermediate‐Risk Prostate Cancer in a Japanese Radical Prostatectomy Cohort: Results From the MICAN Study

    by Tsuyoshi Oono, Masato Terashita, Shinsuke Mori, Akihiro Oka, Shinji Matsuzaki, Akira Yano, Masafumi Matsumura, Iku Ninomiya, Kensuke Shinomori, Tomoko Ogawa, et al.

    Objectives: We aimed to evaluate the prognostic utility of subclassifying patients with intermediate‐risk prostate cancer into favorable and unfavorable subgroups in a large Japanese cohort undergoing radical prostatectomy, focusing on adverse pathology and oncologic outcomes. Methods: We retrospectively analyzed 1485 intermediate‐risk patients from the MICAN (Medical Investigation Cancer Network) study registry who underwent radical prostatectomy between 2010 and 2020 in Ehime Prefecture, Japan. Patients were categorized into favorable or unfavorable intermediate‐risk groups based on the National Comprehensive Cancer Network (NCCN) guideline. We examined up‐grading, up‐staging, and adverse pathology defined as pathological ≥T3, grade group ≥ 4, or lymph node involvement. Kaplan–Meier analysis was used to evaluate prostate‐specific antigen (PSA) failure‐free survival and overall survival. Results: Among 1485 patients, 590 (40.2%) were classified as having favorable intermediate risk and 879 (59.8%) as having unfavorable intermediate risk. Up‐grading and up‐staging were observed more frequently in the unfavorable group. Adverse pathology was more frequent in the unfavorable group (64.8%) than that in the favorable group (39.4%) ( p < 0.001). The 5‐year PSA failure‐free survival rates were 92.1% for the favorable group and 80.1% for the unfavorable group ( p < 0.001). Although the 5‐year overall survival rate did not reach statistical significance (98.4% vs. 97.9%, p = 0.085), the favorable group showed a trend toward better survival. Conclusions: The subclassification of intermediate‐risk prostate cancer into favorable and unfavorable groups is prognostically meaningful in Japanese patients undergoing radical prostatectomy. Higher rates of adverse pathological findings and inferior PSA failure‐free survival in the unfavorable group support the clinical utility of this subclassification.


  • Prognostic significance of non–muscle-invasive late recurrence after intravesical bacillus Calmette–Guérin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group)

    by Yoshinori Ikehata, Naotaka Nishiyama, Makito Miyake, Nobutaka Nishimura, Kita Yuki, Soichiro Shimura, Yuta Inoue, Takashi Matsumoto, Shugo Yajima, Yoshiyuki Nagumo, et al.

    Background: The prognostic significance of non-muscle-invasive bladder cancer (NMIBC) recurrence after a prolonged disease-free interval following intravesical Bacillus Calmette–Guérin (BCG) therapy remains unclear. This multicenter study evaluated the impact of late recurrence after BCG therapy on oncological outcomes. Methods: This retrospective multicenter study used the Japan Urological Oncology Group database. Among 3226 patients treated with intravesical BCG for NMIBC, 238 with non-muscle-invasive intravesical recurrence ≥1 year after initial BCG therapy were analyzed, after excluding those with muscle-invasive recurrence at first recurrence. Patients were stratified by time to recurrence: 1–2 years and ≥ 2 years. Progression-free survival (PFS) and cancer-specific survival (CSS) were assessed using Kaplan–Meier and Cox proportional hazards analyses. Results: During a median follow-up of 72.7 months, the 5-year PFS and CSS rates were 90.8% and 91.5%, respectively. PFS did not differ significantly between the 1–2-year and ≥ 2-year recurrence groups (log-rank p = 0.300). In contrast, recurrence ≥2 years was associated with significantly worse CSS than recurrence at 1–2 years (log-rank P = .018) and was a significant predictor of worse CSS in univariate analysis (hazard ratio, 8.06; 95% confidence interval, 1.02–62.6; P = .047). Repeat BCG therapy did not significantly improve PFS or CSS in patients with recurrence ≥2 years. Conclusions: NMIBC recurrence occurring ≥2 years after initial BCG therapy may be associated with poorer cancer-specific survival despite similar progression-free survival. Late recurrence should not automatically be considered a favorable prognostic subgroup, and careful surveillance and risk stratification are warranted.

  • Open Access

    Pathological Predictors of Limited Salvage Radiotherapy Efficacy After Radical Prostatectomy: Central Review of JCOG0401

    by Masashi Kato, Toyonori Tsuzuki, Akira Yokomizo, Takahiro Kimura, Keita Sasaki, Masaki Shiota, Keiichiro Mori, Takuma Kato, Takashi Kawahara, Dai Koguchi, et al.

    Background/Objectives: The multicenter randomized trial JCOG0401 showed that initial salvage radiotherapy (SRT) before salvage hormonal therapy (SHT) significantly prolonged time to treatment failure (TTF) compared with SHT alone. This central pathology analysis aimed to explore pathological features potentially associated with reduced relative benefit from SRT, while distinguishing prognostic from predictive effects. Methods: We re-analyzed 167 patients from JCOG0401 (SHT: 81, SRT ± SHT: 86). Prostatectomy specimens were re-evaluated, focusing on tertiary Gleason pattern (GP) 5 and intraductal carcinoma of the prostate (IDC-P). Cox proportional hazards models assessed exploratory interaction effects between pathological features and the treatment effect of bicalutamide on TTF. Pathological subgroups in which SRT failed to improve TTF over SHT alone were defined as having reduced benefit from SRT. Results: Adverse pathological features associated with shorter TTF with limited SRT included Gleason score (≥8), GP5, tertiary GP5, IDC-P, positive surgical margins, lymphovascular invasion, and advanced pathological T stage. Exploratory Interaction analyses suggested that IDC-P and tertiary GP5 may be associated with reduced relative benefit from SRT. Among patients without IDC-P, SRT significantly improved TTF (HR 0.330, 95%CI 0.161–0.673), whereas no significant benefit was observed in those with IDC-P (HR: 0.771, 95% CI: 0.446–1.332). Similarly, the absence of tertiary GP5 was associated with a marked benefit from SRT (HR: 0.099, 95% CI: 0.021–0.466), whereas this effect was not observed with tertiary GP5 (HR: 0.760, 95% CI: 0.400–1.443). Conclusions: IDC-P and tertiary GP5 may represent pathological features associated with reduced relative benefit from SRT after radical prostatectomy. These findings are exploratory and hypothesis-generating and require prospective validation in independent cohorts. Careful pathological evaluation may help identify patients who could benefit from treatment intensification or alternative postoperative strategies.

  • Open Access

    Current Treatment Patterns and Outcomes of Sex Cord Stromal Tumor Patients in Japan

    by Takashige Abe, Kosuke Miyai, Toyonori Tsuzuki, Sachiyo Murai, Katsuyoshi Hashine, Shinichi Yamashita, Takashi Kawahara, Naotaka Nishiyama, Hiroshi Kitamura, Hiroshi Kikuchi, et al.

    Objectives: Sex cord‐stromal tumors (SCSTs) constitute approximately 5% of testicular malignancies. This investigation aimed to elucidate contemporary therapeutic approaches and clinical outcomes for patients with testicular SCSTs in Japan. Methods: Participating institutions included Japan Clinical Oncology Group facilities, affiliated centers, and institutions with published cases. Clinical data and histopathological findings were compiled. Central pathological review involved representative tissue sections when available. Kaplan–Meier methodology assessed recurrence‐free survival (RFS) and overall survival (OS). Stage I patients were stratified by cumulative pathological risk factors (tumor diameter ≥ 5 cm, necrosis, moderate to severe nuclear atypia, lymphovascular invasion, infiltrative growth, and ≥ 3 mitoses per 10 high‐power fields). Results: Among 116 patients from 66 institutions, 112 met inclusion criteria. Histological distribution included Leydig cell ( n = 54), Sertoli cell ( n = 36), and other variants ( n = 22). Twelve patients presented with metastatic disease; ten received systemic chemotherapy, with 20.8% five‐year OS. Among 91 stage I patients with follow‐up data, eleven developed recurrence. Patients with > 2 risk factors demonstrated significantly inferior RFS compared with those showing ≤ 1 factor (26.4 versus 98.6% at 5 years, p < 0.0001). Surgical intervention predominated in the recurrent cases (81.8%, 9/11), while chemotherapy was administered to 45.5% (5/11), and selected patients achieved prolonged disease control through repeated surgical resection without systemic therapy. OS rates were 90.9% and 50.5% at 5 and 10 years. Conclusions: Patients with synchronous metastatic presentation demonstrated poor survival. Stage I patients with > 2 pathological risk factors showed reduced RFS, with surgical management potentially efficacious for recurrent disease.


  • Validation of the 7‐Item Quality of Life Disease‐Specific Impact Scale in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Cross‐Sectional Study

    by Sayaka Shimizu, Takahiro Osawa, Miho Sato, Shuhei Yamada, Toru Harabayashi, Jun Miki, Takashi Kobayashi, Katsuyoshi Hashine, Atsunari Kawashima, Takashi Matsumoto, et al.

    Objectives: To validate, for the first time in patients with bladder cancer who underwent radical cystectomy, the recently developed 7‐item Quality of Life Disease‐specific Impact Scale (QDIS‐7), a brief, unidimensional instrument designed for cross‐condition comparisons. Methods: In this cross‐sectional study conducted at 24 facilities, patients aged ≥ 20 years who were 3 months post‐radical cystectomy for bladder cancer completed self‐reported questionnaires. The enrollment period was from January 2020 to October 2022. Quality of life measures included the QDIS‐7, the Bladder Cancer Index (BCI), and the Body Image Scale (BIS). Confirmatory factor analysis was performed to test the hypothesized one‐factor structure of the QDIS‐7. Internal consistency reliability was assessed using Cronbach's alpha coefficient. Criterion‐based validity was evaluated using Spearman's correlation coefficients (ρ) between the QDIS‐7 scores and the BCI bother subdomains and BIS scores. Results: In total, 205 patients (median age, 71 years; 78.5% male) were included. The QDIS‐7 score showed no floor or ceiling effects. Confirmatory factor analysis supported the one‐factor model (factor loadings, 0.71–0.94). Internal consistency reliability was high (Cronbach's alpha, 0.94). The QDIS‐7 score showed moderate correlations with the BIS and the BCI urinary and bowel bother subdomain scores ( ρ = 0.654, −0.560, and −0.475, respectively). Conclusions: The QDIS‐7 effectively captured urinary and bowel symptom burden and body image impairment in patients undergoing radical cystectomy for bladder cancer. Its brevity, strong psychometric properties, and capacity for comparisons across conditions support its use in patient‐centered research. Trail Registration: UMIN‐CTR (UMIN000039538)

  • Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan

    by Taketo Kawai, Jun Miki, Rikiya Taoka, Ryoichi Saito, Wataru Fukuokaya, Yoshiyuki Matsui, Yoichi Fujii, Shingo Hatakeyama, Takashi Kawahara, Ayumu Matsuda, et al.

    Background: Radical cystectomy (RC) remains the standard treatment for muscle-invasive bladder cancer (MIBC), but is highly invasive and may cause functional decline, especially among geriatric patients. This study evaluated age-stratified outcomes of RC through a nationwide, multi-institutional cohort in Japan. Methods: We analyzed 1867 patients with MIBC who underwent RC at 36 institutions, stratified into five age groups: <60, 60–69, 70–74, 75–79, and ≥80 years. The baseline characteristics, perioperative factors, and oncological outcomes were compared. Results: Patients aged ≥80 years had significantly worse overall survival (OS, P < .001), cancer-specific survival (CSS, P = .006), and disease-free survival (DFS, P = .004) after RC. Although preoperative clinical T stage was comparable (P = .22), patients aged ≥80 years less frequently received neoadjuvant chemotherapy (NAC), and more often showed pathological extravesical extension and positive surgical margins (all P < .001). The incidence of grade ≥3 complications and 30-day mortality were comparable, whereas 90-day mortality was higher in this group (P = .047). Multivariable Cox analysis confirmed age ≥80 years as an independent predictor for unfavorable OS (P < .001), CSS (P = .017), and DFS (P = .018). Among patients aged ≥80 years, the use of NAC was associated with better OS (P = .033), particularly in those with Eastern Cooperative Oncology Group performance status of 0 (P = .015). Conclusion: Patients aged ≥80 years had significantly worse oncological outcomes after RC. NAC may improve OS in selected older patients with good performance status.


  • Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy

    by Shuhei Hara, Wataru Fukuokaya, Jun Miki, Rikiya Taoka, Ryoichi Saito, Yoshiyuki Matsui, Shingo Hatakeyama, Takashi Kawahara, Ayumu Matsuda, Taketo Kawai, et al.

    Objective: To examine the association between substaging and outcomes following radical cystectomy (RC) in patients with stage III bladder cancer.Methods: We conducted a retrospective observational study using nationwide data from Japan, including 708 patients with stage III bladder cancer who underwent RC. Substaging was based on the American Joint Committee on Cancer's 8th edition. pT3‐4aN0 and pTanyN1 were newly defined as stage IIIA, while pTanyN2‐3 were defined as stage IIIB. Baseline covariates were balanced using inverse probability of treatment weighting. We analyzed disease‐free survival (DFS) and overall survival (OS) across these substages and among the sub‐groups: pT3‐4aN0, pTanyN1, and pTanyN2‐3.Results: We found evidence that stage IIIB bladder cancer had inferior outcomes than stage IIIA (DFS, hazard ratio, 1.61 [95% confidence interval, 1.28–2.02]; OS, 1.61 [1.25–2.09]). Furthermore, there was evidence of the difference in outcomes between pT3‐4aN0 versus pTanyN2‐3 (DFS, 1.73 [1.35–2.23]; OS, 1.63 [1.23–2.15]), while no evidence of the difference between pT3‐4aN0 and pTanyN1 was observed (DFS, 1.27 [0.96–1.67]; OS, 1.09 [0.78–1.53]). We did not find evidence of heterogeneity in the effects of the substaging on OS by the use of perioperative chemotherapy.Conclusion: This prognostic study supports the current stage III substaging of patients with bladder cancer who underwent RC. Importantly, there was no difference in OS between pT3‐4N0 and pTanyN1 in patients with stage IIIA bladder cancer. These findings may help guide treatment decisions for patients with stage III operable bladder cancer.


  • Open Access

    Patient-reported outcomes after robot-assisted radical prostatectomy and institutional learning curve for functional outcomes

    by Katsuyoshi Hashine, Koki Tada, Ryoei Minato, Yuichiro Sawada, Masafumi Matsumura

    Purpose: The study was performed to examine patient-reported outcomes (PROs) in the 1st year after surgery and the institutional learning curve after the introduction of robot-assisted radical prostatectomy (RARP). Materials and Methods: The subjects were 320 consecutive patients who underwent RARP from 2014 to 2018. These cases were divided into three groups treated in the early, middle, and late periods, with about 100 cases in each. PROs were recorded using the Expanded Prostate Cancer Index Composite (EPIC). Results: There were no significant differences among the early, middle, and late periods based on EPIC scores. Urinary function and bother decreased in the 1st month after surgery, and gradually recovered thereafter. However, urinary function was significantly worse in the 1st year after surgery than at baseline. Urinary function and bother were better in patients treated with nerve-sparing surgery, and in nerve-sparing cases, urinary function and bother were best in the early period and worst in the late period. These cases also had the best score for sexual function in the early period, but sexual bother was worst in the early period. In contrast, in cases treated without nerve-sparing surgery, urinary function and bother were best in the late period and worst in the early period, although without significant differences. Conclusion: The functional results of this study based on PROs are useful for providing information for patients. Interestingly, the institutional learning curves for RARP differed in cases that did and did not undergo a nerve-sparing procedure.


  • Predictive factors for the effectiveness of novel androgen receptor axis‐targeted agents in patients with metastatic prostate cancer

    by Nishimoto Koshiro, Kenichi Nakajima, Masafumi Oyama, Go Kaneko, Satoru Takahashi, Hideyasu Matsuyama, Hiroaki Shiina, Tomohiko Ichikawa, Hiroyuki Horikoshi, Katsuyoshi Hashine, et al.

    Objective Novel androgen receptor axis-targeted agents (ARATAs) have been developed for mCRPC and improved overall survival (OS). Here, we aimed to find predictors who will receive the greatest benefits from ARATAs. Methods We previously performed a multicenter study to identify prognostic factors for metastatic hormone-sensitive prostate cancer (mHSPC, n = 148) and mCRPC (n = 99), and showed that the bone scan index (BSI) was one of the significant prognostic factors for 3-year OS (PROSTAT-BSI study). mHSPC progressed to mCRPC (n = 101), for which 69 patients were treated with (n = 39) or without ARATAs (n = 30, prior to the approval of ARATAs). The 69 patients were divided into two groups according to patient factors, and these cohorts were further divided into two subgroups by usage of ARATAs. OS was compared between subgroups in each group. Results The predictors were age (= 0.16 ng/ml) and alkaline phosphatase (>= 548 U/L), time to PSA progression after ADT (= 1 ng/ml) after ADT, and the rate of PSA decline 3 months after ADT (<0.987), whereas hemoglobin levels, PSA before ADT, Gleason scores, existence of visceral metastases, and BSI were not. Conclusions The present study identified predictors for the effectiveness of ARATAs. The number of bone metastases ( approximately equal to or the image of BSI), existence of visceral metastases, and Gleason scores, which were identified as high-risk factors in the LATITUDE study and disease volume in CHAARTED criteria, did not appear to be useful for predicting effectiveness from ARATAs.